Ameriprise Financial Inc. Sells 17,263 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ameriprise Financial Inc. cut its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,359,782 shares of the medical equipment provider’s stock after selling 17,263 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.67% of Intuitive Surgical worth $1,049,713,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in ISRG. Creekmur Asset Management LLC boosted its position in Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new position in shares of Intuitive Surgical in the second quarter valued at approximately $26,000. Able Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter worth approximately $28,000. Delos Wealth Advisors LLC grew its position in Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares during the last quarter. Finally, LRI Investments LLC acquired a new stake in Intuitive Surgical during the 1st quarter valued at $30,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $484.39 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18. The stock has a market cap of $172.13 billion, a P/E ratio of 87.44, a P/E/G ratio of 5.39 and a beta of 1.39. The firm has a 50 day moving average price of $469.98 and a 200 day moving average price of $426.71.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS. Analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of a number of recent analyst reports. Citigroup boosted their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Robert W. Baird increased their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Truist Financial raised their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $446.45.

Insider Buying and Selling at Intuitive Surgical

In other news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares in the company, valued at approximately $145,113.45. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,120 shares of company stock valued at $25,528,753. Company insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.